Lin BioScience, Inc. Stock price

Equities

6696

TW0006696008

Pharmaceuticals

End-of-day quote Taipei Exchange 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
90.6 TWD -3.72% Intraday chart for Lin BioScience, Inc. -10.30% -20.53%
Sales 2021 - Sales 2022 - Capitalization 12.58B 402B
Net income 2021 -435M -13.89B Net income 2022 -314M -10.03B EV / Sales 2021 -
Net cash position 2021 805M 25.69B Net cash position 2022 1.6B 51.05B EV / Sales 2022 -
P/E ratio 2021
-29.4 x
P/E ratio 2022
-39.8 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.72%
1 week-10.30%
Current month-16.88%
1 month-16.11%
3 months-21.22%
6 months-20.18%
Current year-20.53%
More quotes
1 week
88.80
Extreme 88.8
100.50
1 month
88.80
Extreme 88.8
109.50
Current year
88.80
Extreme 88.8
117.50
1 year
88.80
Extreme 88.8
205.00
3 years
88.80
Extreme 88.8
301.00
5 years
27.00
Extreme 27
301.00
10 years
27.00
Extreme 27
301.00
More quotes
Managers TitleAgeSince
Founder 46 16-05-11
Director of Finance/CFO 38 16-05-31
Chief Operating Officer 43 16-06-30
Members of the board TitleAgeSince
Director/Board Member - 18-09-26
Director/Board Member - 18-09-26
Director/Board Member 52 16-10-12
More insiders
Date Price Change Volume
24-03-28 90.6 -3.72% 909,457
24-03-27 94.1 -3.68% 458,086
24-03-26 97.7 -1.31% 380,939
24-03-25 99 -1.49% 270,706
24-03-22 100.5 -0.50% 132,743

End-of-day quote Taipei Exchange, March 27, 2024

More quotes
LIN BIOSCIENCE, INC. is a Taiwan-based company mainly engaged in the development of new pharmaceutical drugs. The Company is in the research and development and clinical trials stage. It has four major drugs in development, including LBS-008, LBS-007, LBS-009 and LBS-002, as well as two technical platforms of RBP4 and CDC7. LBS-008 is developed for dry macular degeneration which belongs to the best-selling drugs, and stel lesions which belongs to orphan drugs. LBS-007 is used in acute leukemia which belongs to orphan drugs, and solid tumors which belongs to the best-selling drugs. LBS-009 is used in non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and type 2 diabetes. LBS-002 is developed for primary brain cancer and metastatic brain cancer. RBP4 platform is used for metabolic diseases, and CDC7 platform is used for all cancers.
More about the company
  1. Stock
  2. Equities
  3. Stock Lin BioScience, Inc. - Taipei Exchange